QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

DGX

QT66Quest Diagnostics Incorporated
NYSE·Healthcare·Medical - Diagnostics & Research·USA
Latest market price
195.00
-2.76-1.40%
OverviewShort InterestFilings
DGXQT66Quest Diagnostics Incorporated·NYSE
OverviewShort InterestFilings
195.00-1.40%
TA
Loading chart...
Screen all →
TMO+0.63%$464.61DHR-0.33%$177.17IDXX+2.93%$562.09A+2.20%$127.06NTRA+2.19%$231.41IQV-1.70%$167.77ILMN+1.79%$161.93WAT-0.44%$355.44
Snapshot
Index-P/E21.24EPS (ttm)9.05
Insider Own1.07%
Shs Outstand110.70M
Perf Week-4.33%
Market Cap21.89BForward P/E16.71EPS next Y11.67Insider Trans0.00%Shs Float-Perf Month2.42%
Enterprise Value28.48BPEG1.47EPS next Q2.81Inst Own-Short Float-Perf Quarter0.43%
Income1.03BP/S1.94EPS this Y18.76%Inst Trans-Short Ratio-Perf Half Y9.15%
Sales11.28BP/B2.95EPS next Y8.59%ROA6.14%Short Interest-Perf YTD12.37%
Book/sh69.25P/C11.76EPS next 5Y8.36%ROE14.11%52W High213.51 -8.67%Perf Year8.97%
Cash/sh3.55P/FCF16.51EPS past 3/5Y-ROIC8.14%52W Low164.65 18.43%Perf 3Y-
Dividend Est.3.44 (1.76%)EV/EBITDA13.41Sales past 3/5Y3.74% 3.18%Gross Margin33.23%Volatility1.42% 1.56%Perf 5Y-
Dividend TTM3.26 (1.67%)EV/Sales2.53EPS Y/Y TTM31.86%Oper. Margin14.31%ATR (14)4.53Perf 10Y-
Dividend Ex-DateJul 08, 2026Quick Ratio1.08Sales Y/Y TTM14.24%Profit Margin9.08%RSI (14)46.05Recom2.57
Dividend Gr. 3/5Y6.61% 7.35%Current Ratio1.18EPS Q/Q13.12%SMA20-1.29%Beta-0.08Target Price220.57
Payout34.86%Debt/Eq0.95Sales Q/Q9.16%SMA500.07%Rel Volume1.39Prev Close197.76
Employees55,000LT Debt/Eq0.86EarningsJul 28SMA2002.86%Avg Volume926.48KPrice195.00
IPO DateDec 17, 1996Option/ShortYes / YesEPS/Sales Surpr.5.49% 2.33%Net Debt/EBITDA3.10Volume1,288,156Change-1.40%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-21-26ReiteratedEvercore ISI$210 → $225
Apr-21-26ReiteratedJefferiesBuy$220 → $225
Apr-08-26ReiteratedEvercore ISI$220 → $210
Feb-12-26ReiteratedMizuho Securities$210 → $235
Feb-11-26ReiteratedTruist Financial$205 → $220
Feb-11-26ReiteratedEvercore ISI$190 → $220
Feb-11-26ReiteratedRobert W. Baird$203 → $219
Feb-11-26ReiteratedUBSNeutral$190 → $210
Jan-30-26ReiteratedBarclaysEqual Weight$195 → $210
Oct-27-25ReiteratedPiper SandlerNeutral$180 → $200
Latest News
Jun-18-26
Jun-18-2612:57PM
UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest DiagnosticsYahoo
Jun-17-26
Jun-17-2601:00PM
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026Yahoo
Jun-16-26
Jun-16-2601:00PM
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility ReportYahoo
12:30PM
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and GrowthYahoo
Jun-12-26
Jun-12-2609:10AM
Quest Diagnostics Inc (NYSE:DGX): A Top Dividend Stock with Sustainable Income and Growth PotentialChartMill
Jun-10-26
Jun-10-2601:22PM
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, LifeStance Health and Aveanna HealthcareYahoo
Jun-09-26
Jun-09-2602:40PM
4 Outpatient Home Health Stocks Benefiting From Industry TrendsYahoo
02:40PM
4 Outpatient Home Health Stocks Benefiting From Industry TrendsYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue11,27811,0359,872
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A7,5307,5126,628
Gross Profit3,7483,5233,244
Selling, General and Administrative Excl. Other1,9771,9671,770
Research and Development
000
Other Operating Expense157-47128
Operating Income1,6141,6031,346
Interest Expense268277226
Unusual Expense
———
Non-Operating Income (Expense)-42-21-55
Net Income Before Taxes1,4001,3601,194
Income Taxes329314273
Consolidated Net Income1,024992871
Net Income From Continuing Operations1,0711,046921
Net Income1,024992871
EPS (Recurring)9.178.877.80
EPS (Basic, Before Extraordinaries)9.178.877.80
EPS (Diluted)9.058.757.69
EBITDA2,1232,1941,894
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio21.5519.83—
Price To Sales Ratio1.901.75—
Gross Margin33.2331.9332.86
Operating Margin14.3114.5313.63
Net Margin9.088.998.82
Shares Outstanding110111111
Market Capitalization21,45019,262—
Operating Lease Expense
———
Insider Trading Volume
$229.79$203.11$176.43$149.75$123.06● Close Price0.00M3.08M6.16M9.24M12.32MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
KUPPUSAMY KARTHIKSVP, Clinical SolutionsJun 04 '26Option Exercise124.2216,2942,024,00021,657Jun 08 12:00 AM
KUPPUSAMY KARTHIKSVP, Clinical SolutionsJun 04 '26Sale200.008,1471,629,40013,510Jun 08 12:00 AM
Davis J. E.CEO and PresidentJun 01 '26Sale194.1410,0001,941,400132,423Jun 02 12:00 AM
Doherty Catherine T.EVP, Regional BusinessesMar 05 '26Sale206.215,5581,146,11567,122Mar 06 12:00 AM
PREVOZNIK MICHAEL ESVP & General CounselMar 05 '26Sale206.213,878799,68237,557Mar 06 12:00 AM
Plewman PatrickSVP for Diagnostic ServicesMar 05 '26Sale206.212,855588,73015,198Mar 06 12:00 AM
KUPPUSAMY KARTHIKSVP, Clinical SolutionsMar 04 '26Sale204.862,628538,37213,441Mar 06 12:00 AM
Doherty Catherine T.EVP, Regional BusinessesMar 03 '26Sale207.73632131,28567,122Mar 04 12:00 AM
Plewman PatrickSVP for Diagnostic ServicesMar 03 '26Sale207.7341085,16915,198Mar 04 12:00 AM
PREVOZNIK MICHAEL ESVP & General CounselMar 03 '26Sale207.73526109,26637,557Mar 04 12:00 AM
Davis J. E.CEO and PresidentMar 02 '26Sale212.5210,0002,125,200117,185Mar 04 12:00 AM
Plewman PatrickSVP for Diagnostic ServicesFeb 19 '26Sale204.83958196,22715,838Feb 20 12:00 AM
PREVOZNIK MICHAEL ESVP & General CounselFeb 19 '26Sale204.831,111227,56638,371Feb 20 12:00 AM
Doherty Catherine T.EVP, Regional BusinessesFeb 19 '26Sale204.831,433293,52168,402Feb 20 12:00 AM
Doherty Catherine T.EVP, Regional BusinessesFeb 13 '26Option Exercise112.1752,3305,869,85694,233Feb 17 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR